STAAR Surgical CompanySTAANASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-10.27%
↓ 393% below average
Average (39q)
3.50%
Historical baseline
Range
High:74.35%
Low:-32.54%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q4 2025 | -10.27% |
| Q2 2025 | -24.88% |
| Q1 2025 | 13.46% |
| Q4 2024 | -16.93% |
| Q3 2024 | 22.15% |
| Q2 2024 | -11.30% |
| Q1 2024 | 23.14% |
| Q4 2023 | -5.27% |
| Q3 2023 | -2.42% |
| Q2 2023 | 14.02% |
| Q1 2023 | 5.31% |
| Q4 2022 | 1.81% |
| Q3 2022 | 11.35% |
| Q3 2022 | 8.75% |
| Q2 2022 | -12.47% |
| Q4 2021 | 9.68% |
| Q4 2021 | 0.13% |
| Q3 2021 | 0.01% |
| Q2 2021 | -7.80% |
| Q1 2021 | 2.37% |
| Q4 2020 | 19.70% |
| Q3 2020 | 5.99% |
| Q2 2020 | -6.90% |
| Q1 2020 | 20.35% |
| Q3 2019 | 0.95% |
| Q2 2019 | 8.22% |
| Q1 2019 | -1.23% |
| Q4 2018 | 2.42% |
| Q3 2018 | 4.19% |
| Q2 2018 | 6.01% |
| Q1 2018 | -2.87% |
| Q4 2017 | 17.23% |
| Q3 2017 | -6.01% |
| Q2 2017 | -1.48% |
| Q1 2017 | 11.88% |
| Q4 2016 | -4.00% |
| Q3 2016 | -4.42% |
| Q3 2016 | -32.54% |
| Q2 2016 | 74.35% |
| Q1 2016 | 7.52% |